Kraj: Australia
Język: angielski
Źródło: Department of Health (Therapeutic Goods Administration)
Paclitaxel
Actavis Australia Pty Ltd
Medicine Registered
ACTAVIS AUSTRALIA PTY LTD-VERSION 2 PAGE 1 OF 3 PACLITAXEL ACTAVIS _PACLITAXEL _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET The medicine your doctor has prescribed for you is called PACLITAXEL ACTAVIS. The information in this leaflet will answer some questions you may have about PACLITAXEL ACTAVIS. This leaflet does not contain everything about PACLITAXEL ACTAVIS. Your doctor has been provided with full information and can answer any questions you may have. Follow your doctor's advice even if it differs from what is in this leaflet. You should read this leaflet carefully before starting PACLITAXEL ACTAVIS and keep it in a safe place to refer to later. WHAT PACLITAXEL ACTAVIS IS USED FOR PACLITAXEL ACTAVIS is used to treat cancer of the ovary, the breast, and non small cell cancer of the lung. PACLITAXEL ACTAVIS may be used alone or in combination with other anticancer agents. Ask your doctor if you have any questions about why PACLITAXEL ACTAVIS was prescribed for you. _HOW PACLITAXEL _ _ACTAVIS WORKS _ PACLITAXEL ACTAVIS is a new class of anticancer agents known as taxanes. These agents prevent the division of cells, particularly cancer cells. The use of PACLITAXEL ACTAVIS to treat your cancer can lead to side-effects, which are discussed below. HOW PACLITAXEL ACTAVIS IS USED PACLITAXEL ACTAVIS will be administered in a hospital clinic. PACLITAXEL ACTAVIS may be used alone or with other anticancer medicines. Dose The dose is worked out based on your body weight and height, and so may be different from the dose chosen for other people. PACLITAXEL ACTAVIS is administered as an intravenous infusion over a 3 hour period. Administration will occur at 3 week intervals. The administration of PACLITAXEL ACTAVIS requires all patients to be given premedicat Przeczytaj cały dokument
Paclitaxel Actavis , concentrated injection PRODUCT INFORMATION NAME OF THE MEDICINE Paclitaxel Actavis, concentrated injection Active: Paclitaxel Molecular formula: C 47 H 51 NO 14 Molecular weight: 853.929 CAS: 33069-62-4 DESCRIPTION Each vial contains Paclitaxel, PEG-35 castor oil, citric acid anhydrous and ethanol-absolute. Paclitaxel is a natural product with antitumour activity. It is a white to off white crystalline powder that is highly lipophilic and insoluble in water. It is the first of a new class of anticancer agents known as taxanes. PHARMACOLOGY Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers. It stabilises microtubules by preventing depolymerisation, resulting in the inhibition of the normal dynamic reorganisation of the microtubule network essential for cellular functions. Paclitaxel also induces abnormal arrays or 'bundles' of microtubules throughout the cell cycle, and multiple asters of microtubules during mitosis. This can result in arrest of cell division and impaired function of nervous tissue. PACLITAXEL ACTAVIS – Product information Page 2 of 17 PACLITAXEL ACTAVIS/PI/122011/4 PHARMACOKINETICS The pharmacokinetics of paclitaxel have been evaluated over a wide range of doses (up to 300 mg/m 2 ) and infusion schedules (ranging from 3 to 24 hours). Following intravenous administration, paclitaxel exhibits a biphasic decline in plasma concentrations. The initial rapid decline represents distribution to the peripheral compartment and elimination; the later phase is due, in part, to a relatively slow efflux of paclitaxel from the peripheral compartment. Maximum plasma concentrations are related to dose. In patients treated with doses Przeczytaj cały dokument